Biomarker assessment

Why standard blood tests often reassure without informing

Reference ranges on a standard report are built to identify established disease. They are wide, and being inside them tells you that you probably do not have a diagnosable condition today. It says considerably less about whether your metabolic health is heading in the right direction.

Longevity medicine looks at where you sit within those ranges, how markers move over time, and which of them predict future risk rather than current illness.

What is assessed

A comprehensive panel typically covers metabolic markers including fasting glucose, insulin and HbA1c; a full lipid profile with apolipoprotein B and lipoprotein(a), which carry more predictive value than total cholesterol alone; inflammatory markers; liver, kidney and thyroid function; full blood count; iron studies; and vitamin and mineral status including vitamin D and B12.

Hormonal profiling is added where relevant. Body composition and functional measures are recorded alongside the bloods, because a number means little without the person attached to it.

Tests are chosen for what they will change. A marker that would not alter your management is not worth your money, and will not be ordered simply because it is available.

Interpretation and the plan

Results are explained in plain language — what each marker means, which ones matter most for you, and which can be safely ignored. You then get a written plan with specific targets, the interventions intended to move them, and a date to retest.

The retest is the point. A plan without measurement is a guess.

What this is not

Comprehensive testing is not risk-free. Wide panels generate incidental findings, some of which lead to further investigation that turns out to be unnecessary, and a degree of anxiety along the way. Where a test is more likely to worry you than help you, that will be said before it is ordered.

Risks and limitations

No treatment is without risk, and you are entitled to the full picture before you decide rather than a summary afterwards. These are discussed with you individually at consultation, in the context of your own history.

• Incidental findings prompting further investigation that may prove unnecessary
• Anxiety generated by borderline or ambiguous results
• Bruising or discomfort at the blood draw
• The limits of any single snapshot — trends over time carry more meaning
• Some newer markers have a less established evidence base for guiding treatment

Where you would be seen

Longevity consultations, biomarker review and follow-up take place at CLNQ Manchester at Deansgate Square, and at CLNQ Knutsford in Cheshire. Phlebotomy is done on site at both.

Equipment-based longevity treatments, including hyperbaric oxygen and ozone therapy, are delivered at the Manchester Deansgate Square clinic. Patients attend from across Greater Manchester and Cheshire, and parking at New Jackson car park (M15 4NP) is a short walk away.

• CLNQ Manchester — Deansgate Square 11 Owen Street, Manchester M15 4YB Ground floor of the South Tower at Deansgate Square, Manchester city centre.
• CLNQ Knutsford — Cheshire 49-51 King Street, Knutsford WA16 6DX King Street, Knutsford, serving Cheshire and the surrounding area.

Related treatments